Baird raises Taysha Gene Therapies stock price target to $12 on Rett syndrome study
PositiveFinancial Markets

Baird has increased its stock price target for Taysha Gene Therapies to $12 following promising results from a study on Rett syndrome. This is significant as it highlights the potential of Taysha's therapies in addressing this rare neurological disorder, which could lead to improved treatment options for patients and potentially boost investor confidence in the company's future.
— Curated by the World Pulse Now AI Editorial System